Document is current
Any future updates will be listed below
-
Authors
Tharmalingam, Nagendran https://orcid.org/0000-0001-6107-3754
Kovacs, Robert Wilson
Scarpa de Mello, Suelen https://orcid.org/0000-0001-6389-6041
Baldwin, Philip Rupert
Jayanthan, Harikrishna Sekar
Arulsamy, Kulandaisamy
Rajmuthiah, Rajmohan
Rossatto, Fernanda Cristina Possamai
Manz, Katherine E.
DeGiorgis, Joseph A.
Acevedo, Orlando https://orcid.org/0000-0002-6110-3930
Gilmore, Michael S.
Ludtke, Steven J. https://orcid.org/0000-0002-1903-1574
Pennell, Kurt D. https://orcid.org/0000-0002-5788-6397
Ausubel, Frederick M.
Mylonakis, Eleftherios https://orcid.org/0000-0002-4624-0777
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Center for Information Technology (P01 AI083214)
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 19 February 2026
First Online: 15 March 2026
Competing interests
: FMA had a financial interest in Octagon Therapeutics, Inc., a company that was previously engaged in developing antimicrobial compounds. None of the other authors declare financial conflicts of interest.
